FOLH1 and glioblastoma: Promising clinical data have been observed with CAR-T cells targeting IL13RA2 or EGFRv3 in glioblastoma patients20, the disialoganglioside GD2 in neuroblastoma21 and H3K27M-mutated diffuse midline gliomas22, Prostate-specific membrane antigen in metastatic prostate cancer23 and CLDN18.2 in patients with gastrointestinal cancers24.